Evidence map›Paper›PMID 15509303›Full record

ArticleGenetic vaccines and therapy2004

Alain Chapel, Olivier Deas, Morad Bensidhoum, Sabine François, Moubarak Mouiseddine, Pascal Poncet, Antoine Dürrbach, Jocelyne Aigueperse, Patrick Gourmelon, Norbert C Gorin and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genetic vaccines and therapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Gene therapy for radioprotection.Cancer gene therapy · 2015
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alain ChapelInstitut de Radioprotection et de Sûreté Nucléaire, Département de Protection et de santé de l'Homme et de Dosimétrie, Section Autonome de Radiobiologie Appliquée à la Médecine, Fontenay aux roses, France.
Olivier DeasInserm U542 and Paris XI University, Villejuif, France.
Morad BensidhoumLaboratoire de Thérapie Cellulaire et de Radioprotection Accidentelle, LTCRA, UPRES 1632, CHU Saint Antoine, Paris, France.
Sabine FrançoisInstitut de Radioprotection et de Sûreté Nucléaire, Département de Protection et de santé de l'Homme et de Dosimétrie, Section Autonome de Radiobiologie Appliquée à la Médecine, Fontenay aux roses, France.
Moubarak MouiseddineInstitut de Radioprotection et de Sûreté Nucléaire, Département de Protection et de santé de l'Homme et de Dosimétrie, Section Autonome de Radiobiologie Appliquée à la Médecine, Fontenay aux roses, France.
Pascal PoncetInstitut Pasteur, Paris, France.
Antoine DürrbachInserm U542 and Paris XI University, Villejuif, France.
Jocelyne AigueperseInstitut de Radioprotection et de Sûreté Nucléaire, Département de Protection et de santé de l'Homme et de Dosimétrie, Section Autonome de Radiobiologie Appliquée à la Médecine, Fontenay aux roses, France.
Patrick GourmelonInstitut de Radioprotection et de Sûreté Nucléaire, Département de Protection et de santé de l'Homme et de Dosimétrie, Section Autonome de Radiobiologie Appliquée à la Médecine, Fontenay aux roses, France.
Norbert C GorinLaboratoire de Thérapie Cellulaire et de Radioprotection Accidentelle, LTCRA, UPRES 1632, CHU Saint Antoine, Paris, France.
François Hirsch *Inserm U542 and Paris XI University, Villejuif, France.
Dominique Thierry *Institut de Radioprotection et de Sûreté Nucléaire, Département de Protection et de santé de l'Homme et de Dosimétrie, Section Autonome de Radiobiologie Appliquée à la Médecine, Fontenay aux roses, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTargeted gene transfection remains a crucial issue to permit the real development of genetic therapy. As such,

methodsBalb/C mice were injected intravenously, with an anti-mouse c-kit (CD117) monoclonal antibody chemically coupled to a human IL-3 gene-containing plasmid DNA. Mice were sacrificed for tissue analyses at various days after injection of the conjugates.

resultsBy ELISA, the production of human IL-3 was evidenced in the sera of animals 5 days after treatment. Cytofluorometric analysis after

conclusionsThese data clearly indicate that antibody-mediated endocytosis gene transfer allows the expression of the IL-3 transgene into hematopoietic immature cells,

Identifiers

PMID15509303
PMCPMC535535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.